Top 10 Medical Research Report in 2021 from CRI

India appeared to be a profitable destination to major global players, owing to increase in income levels, private sector participation in healthcare, an aging population, and growth of medical tourism. The market is at a nascent stage and fragmented, dependent on imports and limited capabilities for indigenous manufacturing.

It is estimated to reach INR 1,674.63 Bn by 2025, expanding at a compound annual growth rate (CAGR) of ~22.75% during the forecast period. Major players in the market include Opto Circuits Limited, Philips India Limited, Siemens Limited, TTK Healthcare Limited, and Appasamy Associates.

Patient Monitoring Devices Market is expected to project a notable CAGR of 6.2% in 2030.

Patient Monitoring Devices Market to surpass USD 60.3 Billion by 2030 from USD 20.2 billion in 2018 in terms of value growing at a CAGR of 6.2% throughout the forecast period, i.e., 2019-30. A key trend in patient care is the integration of monitoring technologies into smartphones and wireless devices, leading to the introduction of remote monitoring systems, mobile cardiac telemetry devices, mobile personal digital assistant (PDA) systems, outpatient wireless EEG recorders and outpatient event monitors, which are key factors that support market growth.

According to CRI’s market research, ambroxol has been growing rapidly since it entered China. From 2005 to 2014, its annual sales value increased from less than CNY 200 million to CNY 1.26 billion, representing a CAGR of 20.9%. From 2015 to2020, the sales revenue of ambroxol declined in China. By sales value, Boehringer Ingelheim takes up a market share of about 47.75% in the year of 2020.

The rest market share is captured by Chinese companies, among which the top market players are Changzhou Siyao Pharmaceuticals Co., Ltd., Shenyang Xinma Pharmaceutical Co., Ltd., TIPR Pharmaceutical Responsible Co., Ltd. and. Cisen Pharmaceutical Co., Ltd. Ambroxol is sold in China in the dosage forms of injections, solutions, syrups, granules, tablets and capsules mainly. Injections dominate the market.

Nivolumab was first developed by Medarex and Ono Pharmaceuticals. In 2009, Bristol-Myers Squibb acquired these two companies and obtained the patent for Nivolumab. Nivolumab was launched in China in 2018. By 2020, Bristol-Myers Squibb Pharma EEIG is the only manufacturer in the Chinese Nivolumab market.

According to CRI’s market research, after Nivolumab entered the Chinese market, the sales value of Nivolumab in China increased from CNY9.9 million in 2018 to CNY 43.1 million in 2020. The growth rate in 2020 was 52.2%, which slowed down due to the COVID-19 epidemic. The CAGR of Nivolumab’s sales values in China is 108.7 in 2018 to 2020%.

According to CRI’s market survey, the sales value of Recombinant Human Thrombopoietin kept rising after the drug was launched in China. In 2019, it reached CNY 1257 million, representing a CAGR of 40.9% from 2015 to 2019.CRI expects that as the number of patients with thrombopenia increases in China, the demand for Recombinant Human Thrombopoietin will also increase.

Due to the outbreak of COVID-19 in 2020, the normal operation of many hospitals in China has been affected, and the sales of Recombinant Human Thrombopoietin have also been adversely affected.

As per this report, Global Compounding Chemotherapy Market is anticipated to exhibit a CAGR of 6.04% during the review period of 2020 to 2027, to surpass USD 635.58 Million by 2027. The global market growth is driven by the surged incidences of cancer, increasing expenditure on medicine & science and reimbursements, and increased health benefits.

Further, the Compounding chemotherapy market is attributed to the emerging technical advancements, innovations, and strategies to cater to the demands of clinicians.

Europe Hydrogel Market is segmented on the basis of regional analysis into six major regions.

These include UK, Germany, France, Spain, Italy and Rest of Europe. Geographically, UK is expected to dominate the market in Europe over the forecast period, owing to increase in number of investments & expenditure in healthcare sector, expansion in research & development activities, and geriatric population’s preference for disposable lenses are likely to boost the demand for hydrogel in the region.

As estimated, by 2021, the number of patients with depression in China is about 95 million. But its underdiagnosis rate of depression is over 90% due primarily to the low popularization rate of mental illness science, cultural discrimination against sufferers, the backwardness of psychiatric medical technology and insufficient medical resources.Currently, the treatment for depression is mainly antidepressant medication, supplemented by psychotherapy or physical therapy.

Escitalopram is an antidepressant of the selective serotonin reuptake inhibitor class that is mainly used to treat depressive disorder, generalized anxiety disorder or anxiety disorder with agoraphobia.

Live Cell Imaging Market is expected to project a notable CAGR of 8.52% in 2030.

Live Cell Imaging Market to surpass USD 3.67 billion by 2030 from USD 1.7 billion in 2018 at a CAGR of 8.52% throughout the forecast period, i.e., 2019-30. Due to its advantage of providing a detailed study of the cells, live-cell imaging has gained significant attention in the market. Growing research activities around the world have prompted this strategy to be adopted.

Cell Therapy Technologies Market is expected to project a notable CAGR of 14.2% in 2030.

Cell Therapy Technologies Market to surpass USD 6.7 billion by 2030 from USD 2.2 billion in 2018 at a CAGR of 14.2% throughout the forecast period, i.e., 2019-30. Emerging economies such as Australia and China are expected to provide players in the industry with a wide range of growth opportunities powered by their large and rising populations, as well as a rise in the number of clinical trials and personalized medicine investments in these countries.